NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA

Medifocus Inc. ("Medifocus"or the "Company")(TSX
VENTURE:MFS)(OTCQX:MDFZF)announces that it has completed its previously
announced private placement offering of 1,000,000 common shares (the "Shares")
at a price of $0.30 per Share for gross proceeds of $1,000,000. Shares issued in
connection with the private placement will have a hold period in Canada until
December 12, 2011. 


The net proceeds of this offering will be primarily used by Medifocus to
initiate a pivotal phase III clinical trial using its Microfocus APA 1000 System
for the treatment of breast cancer (including all related professional expenses)
and for working capital. 


Medifocus also announces that it has agreed to a debt settlement with certain
third party creditors, employees and service providers. Subject to approval by
the TSX Venture Exchange, Medifocus will issue an aggregate of 4,042,615 common
shares at an average deemed price of $0.66 per common share to settle such
outstanding debts. The common shares issued will be subject to hold periods
pursuant to applicable securities laws as well as the policies of the TSX
Venture Exchange. 


Medifocus owns a patented microwave focusing technology platform (the Adaptive
Phased Array ("APA") technology), which can precisely target and control
microwave energy to cause heating in cancerous tumors anywhere in the body
reliably and repeatedly. The ability to target tumors with a precision
controlled dose of heat can be used to destroy tumors at higher temperatures, to
treat tumors in combination with chemotherapy and/or radiation at moderate
temperatures for increased effectiveness and reduced toxicity and to trigger the
targeted release of therapeutic drugs and genes at tumor sites at lower
temperatures. While the core technology has been licensed from the Massachusetts
Institute of Technology, Medifocus has further refined the precision of the
microwave focusing and control ability and developed a commercial system
dedicated exclusively for the treatment of Breast Cancer. Please visit
www.medifocusinc.com for more details.